MAIA director granted 28,556 stock options

MAIA Biotechnology, Inc. director Cristian Luput received a grant of stock options representing the right to acquire 28,556 shares of common stock.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Cristian Luput received a grant of stock options representing the right to acquire 28,556 shares of common stock. The options were granted on March 31, 2026, with an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable beginning that day until March 31, 2036. This is a compensation-related award rather than an open-market purchase or sale, and leaves Luput holding 28,556 stock options directly following the transaction.

Insider Trade Summary

Grant/Award: 28,556 shares

Grant/Award 1 txn

Insider Luput Cristian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	28,556	$0.00	$0.00

Holdings After Transaction: Stock Options — 28,556 contracts (Direct)

Footnotes (1)

1. F1. The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

Key Figures

Options granted: 28,556 stock options Exercise price: $1.40 per share Underlying shares: 28,556 shares +3 more

6 metrics

Options granted 28,556 stock options Grant on March 31, 2026

Exercise price $1.40 per share Stock options for MAIA common stock

Underlying shares 28,556 shares Common stock underlying granted options

Vesting 100% on grant date Vests March 31, 2026

Expiration date March 31, 2036 Option term end

Options held after grant 28,556 stock options Total derivative holdings following transaction

Key Terms

Stock Options, 2021 Equity Incentive Plan, vest 100% on the date of the grant, exercise price, +1 more

5 terms

Stock Options financial

"security_title": "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing"

vest 100% on the date of the grant financial

"representing the right to buy shares of common stock, vest 100% on the date"

exercise price financial

""conversion_or_exercise_price": "1.4000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA director Cristian Luput report on this Form 4?

Director Cristian Luput reported receiving a grant of stock options for 28,556 underlying MAIA common shares. The award is a compensation-related acquisition, not an open-market trade, and results in Luput directly holding 28,556 stock options following the March 31, 2026 grant.

What is the exercise price of Cristian Luput’s MAIA stock options?

The granted stock options carry an exercise price of $1.40 per share for MAIA common stock. This means Luput can buy up to 28,556 shares at $1.40 each upon exercise, subject to the option terms and the March 31, 2036 expiration date.

When do Cristian Luput’s MAIA stock options vest and become exercisable?

The stock options granted to Cristian Luput vest 100% on the March 31, 2026 grant date and are exercisable beginning as of that date. This immediate vesting allows Luput to exercise the options at any time before their stated March 31, 2036 expiration.

How long do the MAIA stock options granted to Cristian Luput remain outstanding?

The MAIA stock options granted to Cristian Luput on March 31, 2026 expire on March 31, 2036. This gives a 10-year term during which he may choose to exercise the options at the fixed $1.40 per-share exercise price for the underlying common stock.

Is Cristian Luput’s Form 4 transaction in MAIA stock a market purchase or sale?

The Form 4 reports a grant of stock options as compensation, not a market purchase or sale of MAIA shares. The options were awarded at no cost, with a $1.40 exercise price, giving Luput the right to buy common stock in the future if he exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luput Cristian

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.4	03/31/2026		A		28,556		03/31/2026(1)	03/31/2036	Common Stock	28,556	$0	28,556	D

Explanation of Responses:

1. The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Cristian Luput	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)